Sun Pharma is axing its R&D crowd

After cutting out 150 senior executives,Sun Pharmaceutical Industries is yet again axing staff even after acquiring the $3.2-billion acquisition of Ranbaxy Laboratories.

This time, around 15 staff members from research and development department would be asked to leave as Sun Pharma integrates a combined staff base that's 30,000 strong.

"A thorough assessment has been made of current overlaps across the organisation. While all attempts have been made to ensure that most employees are accommodated in various positions, there will be a few who we need to help in the process of actually transitioning out of the organisation,” said company’s spokesperson.

"We have to be realistic and prepare for adverse news ahead," managing director Dilip Shanghvi told analysts on the July 20 conference call.

(Image: Reuters)